Recombinant mutant human tumor necrosis factor

重组改构人肿瘤坏死因子

Report date: 2026/05/20 20:02:01

Base Information

Drug NameRecombinant mutant human tumor necrosis factor
Drug Alias Name注射用重组改构人肿瘤坏死因子Recombinant Mutant Human Tumor Necrosis Factor for Injection重组人肿瘤坏死因子-NCRecombinant tumour necrosis factor-NC天恩福 +[6] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionTumor necrosis factor receptor agonists
TargetsTumor necrosis factor receptor
Therapy Area/IndicationsAscitesPleural EffusionNeoplasm Metastasis +[7] 
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryMainland China
Original Approved Date2004/07/12
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShanghai Weike Biopharmaceutical Co LtdSecond Military Medical University Of Chinese People'S Liberation Army
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Weike Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsAscitesPleural EffusionNeoplasm Metastasis +[6] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeL01
Related LinksN/A